Molecular Mechanisms and Potential Antiviral Strategies of Liquid-Liquid Phase Separation during Coronavirus Infection.

Molecular Mechanisms and Potential Antiviral Strategies of Liquid-Liquid Phase Separation during Coronavirus Infection.

Publication date: Jun 24, 2024

Highly pathogenic coronaviruses have caused significant outbreaks in humans and animals, posing a serious threat to public health. The rapid global spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in millions of infections and deaths. However, the mechanisms through which coronaviruses evade a host’s antiviral immune system are not well understood. Liquid-liquid phase separation (LLPS) is a recently discovered mechanism that can selectively isolate cellular components to regulate biological processes, including host antiviral innate immune signal transduction pathways. This review focuses on the mechanism of coronavirus-induced LLPS and strategies for utilizing LLPS to evade the host antiviral innate immune response, along with potential antiviral therapeutic drugs and methods. It aims to provide a more comprehensive understanding and novel insights for researchers studying LLPS induced by pandemic viruses.

Open Access PDF

Concepts Keywords
Biomolecules Animals
Comprehensive Antiviral Agents
Coronaviruses Antiviral Agents
Drugs COVID-19
Pandemic COVID-19 Drug Treatment
Humans
Immunity, Innate
innate immunity
Liquid-Liquid Extraction
nucleocapsid protein
Phase Separation
SARS-CoV-2
SARS-CoV-2
Signal Transduction

Semantics

Type Source Name
disease MESH Coronavirus Infection
disease MESH infections
disease IDO host
pathway REACTOME Immune System
disease VO Viruses
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH leukemia
disease IDO pathogen
disease MESH PRRs
drug DRUGBANK Fenamole
disease IDO production
disease MESH common cold
disease MESH lung injuries
disease IDO infection
pathway KEGG Viral replication
drug DRUGBANK Coenzyme M
disease VO effective
disease VO Betacoronavirus
drug DRUGBANK Angiotensin II
disease IDO cell
drug DRUGBANK Serine
pathway KEGG Endocytosis
drug DRUGBANK Sulfate ion
disease MESH shock
disease IDO replication
disease IDO process
disease VO efficiency
drug DRUGBANK L-Leucine
disease IDO immune response
drug DRUGBANK ATP
disease MESH viral infections
disease VO time
drug DRUGBANK Tretinoin
disease VO gene
pathway KEGG Apoptosis
drug DRUGBANK N-acetylsulfanilyl chloride
drug DRUGBANK Zinc
disease IDO site
drug DRUGBANK L-Arginine
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)